News stories about Nektar Therapeutics (NASDAQ:NKTR) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Nektar Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.6605773884273 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Two studies show promising results for NKTR-181 (healio.com)
- ETFs with exposure to Nektar Therapeutics : September 13, 2017 (finance.yahoo.com)
- BRIEF-Nektar Therapeutics initiates propel clinical study (reuters.com)
- Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of … (prnewswire.com)
- Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
A number of analysts recently issued reports on the stock. ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 23rd. Jefferies Group LLC restated a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a research report on Friday, August 18th. Evercore ISI began coverage on shares of Nektar Therapeutics in a research report on Thursday, August 17th. They issued an “in-line” rating and a $20.00 target price for the company. Finally, Zacks Investment Research cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $26.10.
Nektar Therapeutics (NASDAQ:NKTR) opened at 22.05 on Friday. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $24.88. The stock’s market cap is $3.45 billion. The stock has a 50 day moving average of $20.16 and a 200 day moving average of $19.57.
Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The firm had revenue of $34.60 million for the quarter, compared to analysts’ expectations of $33.64 million. During the same quarter in the previous year, the firm posted ($0.36) EPS. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. Equities analysts expect that Nektar Therapeutics will post ($0.94) earnings per share for the current year.
In other news, SVP Stephen K. Doberstein sold 1,701 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total transaction of $32,863.32. Following the completion of the sale, the senior vice president now owns 31,102 shares in the company, valued at approximately $600,890.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Ivan P. Gergel sold 45,080 shares of the business’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $21.08, for a total value of $950,286.40. Following the sale, the senior vice president now owns 51,961 shares of the company’s stock, valued at approximately $1,095,337.88. The disclosure for this sale can be found here. Insiders have sold a total of 320,962 shares of company stock valued at $6,615,210 in the last quarter. Company insiders own 6.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/09/17/nektar-therapeutics-nktr-getting-somewhat-favorable-news-coverage-analysis-finds.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.